University of Iowa Research Foundation

Rensselaer Polytechnic Institute

Massachusetts Institute of Technology

Other

The University of North Carolina at Chapel Hill

Vascular Vision Pharmaceutical Company

University of California

Minnesota Mining and Manufacturing Company

University of Michigan

The General Hospital Corporation

Children's Medical Center Corporation

Nutech Ventures

Nspc Technologies, LLC

Kabio R&d Soo Co., Ltd.

Robert J Linhardt

Jonathan S Dordick

Robert Samuel Langer

Charles L Cooney

Trevor John Simmons

Ramnath Sasisekharan

Daniel L Lohse

Shaker Ahmed Mousa

Helene G Bazin

Parrish M Galliher

Kevin Li

Tulay Polat

Makoto Hirakane

Li Fu

Daisuke Mori

Jian Liu

Seok-Joon Kwon

Brett D Martin

Fuming Zhang

Caitlyn A Chapman

Yuguo Du

Minoru Miyauchi

Chiara Diamante Mancinelli

Ranodhi Nilochani Udangawa

John M Weiler

Charles Frederick Willard

Kam W Leong

Thomas V Doherty

Sang-hyun Lee

Masao Yafuso

Michael P Bevilacqua

Howard Steven Rosen

Wilhelm Pickenhagen

Merton Bernfield

Yeong Shik Kim

Yongmei Xu

Richard M Nelson

Cornelius L Van Gorp

Damodar R Patil

Lacy Daniels

David G Rethwisch

Fikri Avci

Hari G Garg

Jinghua Chen

William J Sonstein

Lunyin Yu

Michael R Buchanan

Stephanie J Brister

Arthur Grant

Michael D Klein

Navdeep Grover

Zohar M Merchant

Payel Datta

Murali Sharath

Jong Hwan Kwak

Elena Paskaleva

Lei Lin

Paul Brodfuehrer

Edward Harris

Akihiro Onishi

Iontcho R Vlahov

Jianjun Miao

Yaping Chen

Rory M Marks

Jong-Won Lee

Terence Maguire

Zhenyu Wang

Friedrich Mayerl

Gerald Fitzgerald

Marc Douaisi

Margaret M Flanagan

Ujjwal Bhaskar

Barbara A Bryan

Ava M Munoz

Kyung-Bok Lee

Ali Al-Hakim

Charles A Hales

Duraikkannu Loganathan

A network of microfibers are fabricated with a core-shell construction from sustainable materials, where the core includes a phase-change material, such as coconut oil, and the shell includes a biomass, such as cellulose. The microfibers are made via a wet-wet electrospinning process utilizing a coaxial spinneret with an inner conduit and an outer conduit. The biomass and the phase-change material are coaxially extruded into a coagulation bath including a mixture of ethanol and water. The collected microfibers exhibit a beaded structure of PCM aggregates and biomass connecting regions between the aggregates and are effective to aid in the thermoregulation of the immediate environment surrounding the network. The microfibers are suitable for use in a variety of sustainable products such as wearable thermoregulating textiles, wall/ceiling panels, insulation, packaging material, and more.

Method of making a microfiber including biomass

The present disclosure relates to synthesis of heparin, which may be bioequivalent to porcine USP Heparin Sodium. The synthesis may involve three intermediates starting from heparosan.

Biosynthetic heparin

A heparin structure with increased anticoagulant activity and method of making the same are disclosed. A heparin sample is provided and treated with a heparan sulfate sulfotransferase in an enzymatic reaction to add sulfuryl groups from a sulfuryl group source to the heparin sample, resulting in a heparin structure having above about 8% more 3-O-sulfo groups relative to wild-type bovine intestinal heparin. The added sulfuryl groups modify the heparin structure and increase the sample's binding to antithrombin III and its anticoagulant activity to be more similar and a viable alternative to porcine intestinal heparin. The modified heparin exhibits an anti-FXa activity and an anti-FIIa activity greater than about 180 U/mg, and a ratio of the anti-FXa activity to the anti-FIIa activity of about 0.9 to about 1.1, consistent with U.S. Pharmacopeia (USP) heparin activity specifications.

Enzymatic preparation of increased anticoagulant bovine sourced heparin

Methods and systems for producing beaded polymeric fibers with advanced thermoregulating properties

The invention encompasses methods and test strips for detecting the presence of cerebrospinal fluid (CSF) in a biological sample comprising removing sialo-transferrin and selectively detecting or measuring asialo-transferrin in the biological sample.

Detection of cerebrospinal fluid

Provided are a conjugate including a core and sialic acids or derivatives thereof bound to the surface of the core, and use thereof. The conjugate provided in the present invention binds with hemagglutinin on the surface of influenza virus to inhibit the course of infection of influenza virus, thereby preventing or treating infection of influenza virus and also preventing or treating infection of influenza virus resistant to antiviral agents. Accordingly, the conjugate may be widely used in the development of prophylactic or therapeutic agents for influenza virus infection.

Conjugate including core and sialic acid or derivative thereof bound to surface of core and use thereof

Methods and systems for synthesizing heparin compounds are provided. The chemoenzymatic synthesis of structurally homogeneous low molecular weight heparins that have a reversible anticoagulant activity is provided. Also disclosed are heparin compounds having anticoagulant activity, including a binding affinity to antithrombin and an anti-Xa activity, but no detectable anti-lla activity. Additionally, provided are synthetic, low-molecular weight heparin compounds with reversible anticoagulant activity, where the anticoagulant activity is reversible by protamine.

Reversible heparin molecules and methods of making and using the same

Embodiments of the invention provide a cellulose-sheathed carbon nanotube fiber. One aspect of the invention provides a sheathed nanotube fiber comprising: a carbon nanotube fiber; and a cellulose sheath extending co-axially along at least a first portion of a length of the carbon nanotube fiber. Another aspect of the invention provides a method of forming a sheathed carbon nanotube fiber, the method comprising: co-electrospinning a carbon nanotube fiber gel core within a cellulose solution sheath.

Cellulose sheathed nanotube fiber

A method for the production of heparosan from fermentation culture ofK5 suitable for industrial production, exhibiting superior yield and purity, smaller culture volumes, faster growth, and lower costs.

K5 heparosan fermentation and purification

Heparin is synthesized from a polysaccharide comprised of a 1-4 glycosidically linked alternating polymer of uronic acid and glucosamine residues, wherein the uronic acid is selected from iduronic and glucuronic acid, wherein the glucosamine is partially N-sulfated; by a series of selective reactions catalyzed by recombinant enzymes.

Enzymatic synthesis of sulfated polysaccharides

The invention is directed a synthetic wood composite comprising biomimetic macromolecules and methods for the preparation thereof.

Synthetic wood composite

A filter and a method of forming a suture structure. The filter includes layered structure(s) interior to the filter. Each layered structure includes a carbon structure comprising carbon and a coating on a surface of the carbon structure. Each layered structure may further include a heparin layer that includes heparin and is on the coating. The coating of the filter includes cellulose, PMMA, PEMA, or PHEMA. The carbon structure may include an activated charcoal layer or carbon nanotube(s). The layered structure is configured to remove a contaminant flowing through the filter. The method of forming the suture structure includes forming a film on a suture that has been previously formed on a mammal. The film includes both a coating on the suture and a heparin layer that includes heparin and is on the coating. The coating of the suture structure includes cellulose, PMMA, PEMA, or PHEMA.

Filter composites for drug detoxification

A silver nanocomposite, a formation method for forming the silver nanocomposite, and an application method utilizing the silver nanocomposite. The silver nanocomposite includes a silver nanoparticle conjugated to a glycosaminoglycan (GAG) or glucose. The formation method includes chemically reacting silver nitrate with a reducing agent to form a silver nanoparticle conjugated to the reducing agent of a GAG or glucose. The application method may include topically applying the silver nanocomposite to a wound or burn as an anti-microbial with respect to an antibiotic-resistant genotype in the wound or burn, wherein the silver nanocomposite topically applied includes the silver nanoparticle conjugated to the GAG of 2,6-diaminopyridinyl heparin (DAPHP) or hyaluronan (HA). The application method may include applying the silver nanocomposite as a coating to plastic, a catheter, or a surgical tool, wherein the silver nanocomposite applied as the coating includes the silver nanoparticle conjugated to the GAG of DAPHP.

Silver nanoparticles as anti-microbial

A single, reproducible scheme to simultaneously purify all three of the heparin lyases from F. heparinum to apparent homogeneity is disclosed herein. The kinetic properties of the heparin lyases have been determined as well as the conditions to optimize their activity and stability. Mono-clonal antibodies to the three heparinases are also described and are useful for detection, isolation and characterization of the heparinases.

Purification, composition and specificity of Heparinase I, II, and III from Flavobacterium heparinum

Growing community of inventors

Albany, NY, United States of America

Robert J Linhardt